Provided by Tiger Trade Technology Pte. Ltd.

Ultragenyx Pharmaceutical

19.30
-0.0800-0.41%
Post-market: 19.300.00000.00%16:31 EDT
Volume:3.65M
Turnover:70.83M
Market Cap:1.86B
PE:-3.31
High:19.77
Open:19.48
Low:19.13
Close:19.38
52wk High:42.37
52wk Low:18.29
Shares:96.63M
Float Shares:93.07M
Volume Ratio:1.58
T/O Rate:3.92%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-5.8316
EPS(LYR):-5.8316
ROE:-608.47%
ROA:-22.03%
PB:-23.31
PE(LYR):-3.31

Loading ...

Ultragenyx provides corporate update, catalysts for 2026

TIPRANKS
·
Jan 12

BRIEF-Ultragenyx Provides Financial And Business Updates At J.P. Morgan Annual Healthcare Conference

Reuters
·
Jan 12

Ultragenyx Pharmaceutical Inc - Cash and Investments About $735 Mln as of Dec 31, 2025

THOMSON REUTERS
·
Jan 12

Ultragenyx Provides Financial and Business Updates at J.P. Morgan Annual Healthcare Conference

GlobeNewswire
·
Jan 12

Ultragenyx price target lowered to $50 from $55 at Morgan Stanley

TIPRANKS
·
Jan 08

RBC Cuts Price Target on Ultragenyx Pharmaceutical to $35 From $72, Keeps Outperform, Speculative Risk

MT Newswires Live
·
Jan 08

Ultragenyx CFO Howard Horn Reports Sale of Common Shares

Reuters
·
Jan 06

Ultragenyx Pharma Is Maintained at Buy by Guggenheim

Dow Jones
·
Jan 05

Benzinga Bulls And Bears: Nike, SpaceX, Ultragenyx — And Chinese Tech Stocks Slide

Benzinga_recent_news
·
Jan 03

Ultragenyx Pharma Is Maintained at Buy by B of A Securities

Dow Jones
·
Jan 03

Two Phase 3 Trial Failures Halve Stock Price; Jefferies Sees Ultragenyx (RARE.US) Rebounding in 2026 with Pipeline Candidates, Initiates "Buy" Rating

Stock News
·
Dec 31, 2025

Ultragenyx Completes Rolling BLA Submission to FDA for DTX401 Gene Therapy

Reuters
·
Dec 31, 2025

Ultragenyx Completes Rolling Submission of Biologics License Application (Bla) to U.S. FDA for Dtx401 Aav Gene Therapy for Glycogen Storage Disease Type Ia (Gsdia)

THOMSON REUTERS
·
Dec 31, 2025

Wall Street's Top Analysts Latest Ratings: DigitalBridge Downgraded

Deep News
·
Dec 31, 2025

Ultragenyx Pharma Is Maintained at Buy by Jefferies

Dow Jones
·
Dec 30, 2025

The Market Doesn't Like What It Sees From Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) Revenues Yet As Shares Tumble 43%

Simply Wall St.
·
Dec 30, 2025

Ultragenyx Pharmaceutical Inc : Piper Sandler Cuts Target Price to $75 From $105

THOMSON REUTERS
·
Dec 30, 2025

Brand Engagement Network, Ultragenyx, Cemtrex, Sidus Space And Tesla: Why These 5 Stocks Are On Investors' Radars Today

Benzinga_recent_news
·
Dec 30, 2025

Barclays Cuts Price Target on Ultragenyx Pharmaceutical to $44 From $50, Keeps Overweight Rating

MT Newswires Live
·
Dec 30, 2025

Ultragenyx Pharmaceutical Down Over 44%, on Track for Record Low Close And Record Percent Decrease -- Data Talk

Dow Jones
·
Dec 30, 2025